214 related articles for article (PubMed ID: 33505906)
1. Case Report: Significant Response to the Combination of Lenvatinib and Immune Checkpoint Inhibitor in a Patient With Heavily Pretreated Metastatic Triple Negative Breast Cancer.
Lee JS; Yost SE; Yuan Y
Front Oncol; 2020; 10():582185. PubMed ID: 33505906
[TBL] [Abstract][Full Text] [Related]
2. A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor-Positive Metastatic Triple-Negative Breast Cancer.
Yuan Y; Lee JS; Yost SE; Frankel PH; Ruel C; Egelston CA; Guo W; Gillece JD; Folkerts M; Reining L; Highlander SK; Robinson K; Padam S; Martinez N; Tang A; Schmolze D; Waisman J; Sedrak M; Lee PP; Mortimer J
Oncologist; 2021 Feb; 26(2):99-e217. PubMed ID: 33141975
[TBL] [Abstract][Full Text] [Related]
3. Combination of pembrolizumab and lenvatinib is a potential treatment option for heavily pretreated recurrent and metastatic head and neck cancer.
Chen TH; Chang PM; Yang MH
J Chin Med Assoc; 2021 Apr; 84(4):361-367. PubMed ID: 33496513
[TBL] [Abstract][Full Text] [Related]
4. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
Lee CH; Shah AY; Rasco D; Rao A; Taylor MH; Di Simone C; Hsieh JJ; Pinto A; Shaffer DR; Girones Sarrio R; Cohn AL; Vogelzang NJ; Bilen MA; Gunnestad Ribe S; Goksel M; Tennøe ØK; Richards D; Sweis RF; Courtright J; Heinrich D; Jain S; Wu J; Schmidt EV; Perini RF; Kubiak P; Okpara CE; Smith AD; Motzer RJ
Lancet Oncol; 2021 Jul; 22(7):946-958. PubMed ID: 34143969
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
Isaacs J; Anders C; McArthur H; Force J
Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
[TBL] [Abstract][Full Text] [Related]
6. Durable Response to Programmed Death 1-Directed Antibodies in a Hypermutated Triple-Negative Breast Cancer: A Case Report.
Platteter E; Wulf G
Case Rep Oncol; 2024; 17(1):392-398. PubMed ID: 38435448
[TBL] [Abstract][Full Text] [Related]
7. Pilot clinical trial and phenotypic analysis in chemotherapy-pretreated, metastatic triple-negative breast cancer patients treated with oral TAK-228 and TAK-117 (PIKTOR) to increase DNA damage repair deficiency followed by cisplatin and nab paclitaxel.
Lang JD; Nguyen TVV; Levin MK; Blas PE; Williams HL; Rodriguez ESR; Briones N; Mueller C; Selleck W; Moore S; Zismann VL; Hendricks WPD; Espina V; O'Shaughnessy J
Biomark Res; 2023 Jul; 11(1):73. PubMed ID: 37491309
[TBL] [Abstract][Full Text] [Related]
8. Response to lenvatinib and pembrolizumab combination therapy in pembrolizumab-pretreated relapsed endometrial cancer.
Mimura K; Shimomura A; Gota T; Ando K; Kawamura Y; Taniyama T; Oishi H; Shimizu C
Gynecol Oncol Rep; 2022 Dec; 44():101084. PubMed ID: 36277029
[TBL] [Abstract][Full Text] [Related]
9. Checkpoint inhibitor therapy for metastatic triple-negative breast cancer.
Heeke AL; Tan AR
Cancer Metastasis Rev; 2021 Jun; 40(2):537-547. PubMed ID: 34101053
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibition in early-stage triple-negative breast cancer.
Varma R; Wright M; Abraham J; Kruse M
Expert Rev Anticancer Ther; 2022 Nov; 22(11):1225-1238. PubMed ID: 36278877
[TBL] [Abstract][Full Text] [Related]
11. Emerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer.
Cipriano É; Mesquita A
Breast Cancer (Auckl); 2021; 15():11782234211002491. PubMed ID: 33814914
[TBL] [Abstract][Full Text] [Related]
12. Lenvatinib- and vadimezan-loaded synthetic high-density lipoprotein for combinational immunochemotherapy of metastatic triple-negative breast cancer.
Zheng C; Zhang W; Wang J; Zhai Y; Xiong F; Cai Y; Gong X; Zhu B; Zhu HH; Wang H; Li Y; Zhang P
Acta Pharm Sin B; 2022 Sep; 12(9):3726-3738. PubMed ID: 36176911
[TBL] [Abstract][Full Text] [Related]
13. Long-term response to sintilimab, bevacizumab and chemotherapy in heavily pretreated microsatellite stable colon cancer.
Cui Z; Wang Q; Deng M; Meng E; Liu S; Niu B; Han Q
Immunotherapy; 2023 Feb; 15(3):127-133. PubMed ID: 36722149
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitors in first-line therapies of metastatic or early triple-negative breast cancer: a systematic review and network meta-analysis.
Liang X; Chen X; Li H; Li Y
Front Endocrinol (Lausanne); 2023; 14():1137464. PubMed ID: 37229447
[TBL] [Abstract][Full Text] [Related]
15. Role of Immunotherapy in the Treatment of Triple-Negative Breast Cancer: A Literature Review.
K Patel K; Hassan D; Nair S; Tejovath S; Kahlon SS; Peddemul A; Sikandar R; Mostafa JA
Cureus; 2022 Nov; 14(11):e31729. PubMed ID: 36569674
[TBL] [Abstract][Full Text] [Related]
16. The emerging role of immune checkpoint inhibitors for the treatment of breast cancer.
Howard FM; Villamar D; He G; Pearson AT; Nanda R
Expert Opin Investig Drugs; 2022 Jun; 31(6):531-548. PubMed ID: 34569400
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence.
Farshbafnadi M; Pastaki Khoshbin A; Rezaei N
Int Immunopharmacol; 2021 Sep; 98():107876. PubMed ID: 34146865
[TBL] [Abstract][Full Text] [Related]
18. Successful Retreatment of Metastatic Triple-negative Breast Cancer With Immune Checkpoint Inhibitors and Chemotherapy.
Nozaki Y; Yamamuro M; Tanaka N; Kamo N; Konishi J
Cancer Diagn Progn; 2023; 3(3):387-391. PubMed ID: 37168973
[TBL] [Abstract][Full Text] [Related]
19. Pembrolizumab plus lenvatinib for radically unresectable or metastatic renal cell carcinoma in the Japanese population.
Fujiwara R; Yuasa T; Kobayashi K; Yoshida T; Kageyama S
Expert Rev Anticancer Ther; 2023 May; 23(5):461-469. PubMed ID: 37038721
[TBL] [Abstract][Full Text] [Related]
20. Current State of Knowledge on the Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer Treatment: Approaches, Efficacy, and Challenges.
Uchimiak K; Badowska-Kozakiewicz AM; Sobiborowicz-Sadowska A; Deptała A
Clin Med Insights Oncol; 2022; 16():11795549221099869. PubMed ID: 35721387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
